Drugs / JZP341
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05631327 | Dec 2022 → Apr 2024 | metastatic neoplasm, neoplasm | Jazz Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JZP341 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05631327 ↗ |
| Route | Intravenous | “administered as a single, intravenous infusion” NCT05631327 ↗ |